Cosmo Pharmaceuticals NV
SIX:COPN
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Salesforce Inc
NYSE:CRM
|
Technology
|
| US |
|
UiPath Inc
NYSE:PATH
|
Technology
|
| US |
|
General Motors Co
NYSE:GM
|
Automobiles
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pharmaceuticals
|
| US |
|
Baxter International Inc
NYSE:BAX
|
Health Care
|
| US |
|
Marathon Petroleum Corp
NYSE:MPC
|
Energy
|
| US |
|
Valero Energy Corp
NYSE:VLO
|
Energy
|
| US |
|
VICI Properties Inc
NYSE:VICI
|
Real Estate
|
| CA |
|
Shopify Inc
NYSE:SHOP
|
Technology
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
Pharmaceuticals
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Micron Technology Inc
NASDAQ:MU
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.9
79.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Salesforce Inc
NYSE:CRM
|
US |
|
|
UiPath Inc
NYSE:PATH
|
US |
|
|
General Motors Co
NYSE:GM
|
US |
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
US |
|
|
Baxter International Inc
NYSE:BAX
|
US |
|
|
Marathon Petroleum Corp
NYSE:MPC
|
US |
|
|
Valero Energy Corp
NYSE:VLO
|
US |
|
|
VICI Properties Inc
NYSE:VICI
|
US |
|
|
Shopify Inc
NYSE:SHOP
|
CA |
|
|
Merck & Co Inc
NYSE:MRK
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Micron Technology Inc
NASDAQ:MU
|
US |
This alert will be permanently deleted.
Cosmo Pharmaceuticals NV
Gross Margin
Cosmo Pharmaceuticals NV
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | IE |
| Market Cap | 1B CHF |
| Gross Margin |
77%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Gross Margin |
-3%
|
| Country | US |
| Market Cap | 710.5B USD |
| Gross Margin |
81%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Gross Margin |
56%
|
| Country | DK |
| Market Cap | 3.3T DKK |
| Gross Margin |
85%
|
| Country | US |
| Market Cap | 373.5B USD |
| Gross Margin |
69%
|
| Country | US |
| Market Cap | 251.1B USD |
| Gross Margin |
77%
|
| Country | CH |
| Market Cap | 202.7B CHF |
| Gross Margin |
73%
|
| Country | CH |
| Market Cap | 183.3B CHF |
| Gross Margin |
75%
|
| Country | UK |
| Market Cap | 162.4B GBP |
| Gross Margin |
82%
|
| Country | IE |
| Market Cap | 146B USD |
| Gross Margin |
68%
|
Cosmo Pharmaceuticals NV
Glance View
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Cosmo Pharmaceuticals NV's most recent financial statements, the company has Gross Margin of 77%.
You don't have any saved screeners yet
